Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Net Margin (2018 - 2025)

Arcturus Therapeutics Holdings' Net Margin history spans 8 years, with the latest figure at 404.1% for Q4 2025.

  • For Q4 2025, Net Margin fell 27230.0% year-over-year to 404.1%; the TTM value through Dec 2025 reached 80.19%, down 2704.0%, while the annual FY2025 figure was 80.19%, 2705.0% down from the prior year.
  • Net Margin reached 404.1% in Q4 2025 per ARCT's latest filing, down from 78.41% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 74.02% in Q4 2022 to a low of 2711.14% in Q1 2021.
  • Average Net Margin over 5 years is 541.39%, with a median of 79.0% recorded in 2025.
  • Peak YoY movement for Net Margin: crashed -235355bps in 2021, then surged 260507bps in 2022.
  • A 5-year view of Net Margin shows it stood at 649.72% in 2021, then soared by 111bps to 74.02% in 2022, then tumbled by -151bps to 37.85% in 2023, then plummeted by -248bps to 131.8% in 2024, then crashed by -207bps to 404.1% in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Net Margin are 404.1% (Q4 2025), 78.41% (Q3 2025), and 32.44% (Q2 2025).